Int J Oral Surg:口腔癌的治疗方式的选择:边缘或节段性切除

2017-12-30 MedSci MedSci原创

对于大多数口腔癌来说,手术是初步明确的治疗方式。在颌骨可能涉及的口腔癌肿瘤切除方面,最重要的是下颌骨的处理。

对于大多数口腔癌来说,手术是初步明确的治疗方式。在颌骨可能涉及的口腔癌肿瘤切除方面,最重要的是下颌骨的处理。

本研究通过系统回顾和荟萃分析的方法探讨了边缘下颌骨切除术患者与行下颌骨节段切除术患者的生存率和疾病控制的差异。共确定了15项队列研究,包括1672名参与者。 Meta分析提供了有利于局部控制的节段性下颌骨切除术的有力证据。当骨髓侵袭时,节段性下颌骨切除术比边缘下颌骨切除术的生存率高73%(P = 0.04)。虽然结果有趋势地显示节段性下颌骨切除可使整体生存率增加23%,但两种不同的下颌骨切除方法的总体生存率之间没有统计学差异。结果发现,边缘下颌骨切除术可用于下颌皮质无侵入或浅表浸润的病例,而下颌骨节段性切除术用于广泛的下颌皮质入侵或髓质浸润的病例更合理。

原始出处:

L. Gou, W. Yang, et al. Marginal or segmental mandibulectomy: treatment modality selection for oral cancer: a systematic review and meta-analysis. International Journal of Oral and Maxillofacial Surgery. 2018 January. doi:http://dx.doi.org/10.1016/j.ijom.2017.07.019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1975789, encodeId=dfe619e578970, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Sep 13 06:28:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308207, encodeId=b36530820e7f, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Apr 22 11:59:10 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020325, encodeId=523820203250d, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 24 08:28:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273902, encodeId=9fd32e3902c4, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Dec 30 16:24:38 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2018-09-13 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1975789, encodeId=dfe619e578970, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Sep 13 06:28:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308207, encodeId=b36530820e7f, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Apr 22 11:59:10 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020325, encodeId=523820203250d, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 24 08:28:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273902, encodeId=9fd32e3902c4, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Dec 30 16:24:38 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2018-04-22 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1975789, encodeId=dfe619e578970, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Sep 13 06:28:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308207, encodeId=b36530820e7f, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Apr 22 11:59:10 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020325, encodeId=523820203250d, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 24 08:28:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273902, encodeId=9fd32e3902c4, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Dec 30 16:24:38 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2018-04-24 小几洁
  4. [GetPortalCommentsPageByObjectIdResponse(id=1975789, encodeId=dfe619e578970, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Sep 13 06:28:00 CST 2018, time=2018-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=308207, encodeId=b36530820e7f, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Apr 22 11:59:10 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020325, encodeId=523820203250d, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Tue Apr 24 08:28:00 CST 2018, time=2018-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273902, encodeId=9fd32e3902c4, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Dec 30 16:24:38 CST 2017, time=2017-12-30, status=1, ipAttribution=)]
    2017-12-30 天涯183

    非常好的文章.学习了

    0

相关资讯

Sci Rep:口腔微生物的变化与口腔癌的发生密切相关

单个细菌和微生物组成的变化与人类疾病(包括癌症)有关。为了揭示口腔菌群失调和口腔鳞状细胞癌(OSCC)之间潜在的关系,本研究从OSCC患者与解剖学相匹配的正常人群中分别获得癌变样本和健康样本进行分析。研究人员使用新一代测序技术在物种水平上对OSCC病变表面样品中的细菌进行分析,以全面研究这些样品中的细菌群落组成和功能基因。结果显示,与正常样品相比,在癌症样本中明显观察到更大的细菌多样性。与以前的研

Plos One:EB病毒感染和口腔鳞状细胞癌的风险密切相关!

EB病毒(EBV)感染与口腔鳞状细胞癌(OSCC)风险之间的相关性在不同的文献报道中是不一致的。近期,一篇发表在杂志Plos One上的文章对这一问题进行了荟萃分析。研究者们在2017年3月31日之前对英文和中文出版物的电子数据库进行了文献检索,以纳入合格的病例对照研究。使用基于异质性的固定或随机效应模型,估计合并的优势比(OR)和95%置信区间(95%CI)确定EBV感染与OSCC风险之间的关联

CLIN CANCER RES:口腔鳞状细胞癌对曲美替尼治疗的肿瘤反应

口腔鳞状细胞癌(OCSCC)中Ras/MEK/ERK通路活化很常见。CLIN CANCER RES近期发表了一篇文章,报道使用MEK抑制剂曲美替尼新辅助治疗口腔鳞状细胞癌的肿瘤反应。

PLoS One:研究人员成功建立了一种可无创早期检测OSCC的方法

口腔鳞状细胞癌(OSCC)约占口腔恶性病变的90%,是世界第六大常见恶性肿瘤。若不能及时做出诊断则会导致死亡率的升高,因此,有必要开发可特异性并敏感性检测OSCC的生物标记物以提高早期发现率。流行病学调查显示,匈牙利人群是世界上OSCC发病率和死亡率最高的人群,因此,本研究旨在寻找适合匈牙利人群的唾液蛋白生物标志物。在这项研究中,研究人员先前报道了14个蛋白在OSCC患者唾液中显著升高。使用基于L

JAMA:烟草使用或可增加HPV-16感染的风险

近日研究发现,研究参与者称使用烟草或暴露于更高含量的烟草生物标志物中的人群更易患性传播感染性疾病,人口腔乳头瘤病毒(HPV-16),该研究发表在10月8日《美国医学协会杂志》上,该论文主题是有关传染病的问题。 在美国,HPV-16病毒被认为是患口腔鳞状细胞癌发病率增加的主因。论文中的背景信息告诉我们,目前每天吸烟人数的自我报告数量和人口腔乳头状瘤病毒患病率之间的关系。 Carole Fakhr

NEJM:选择性颈清扫术更适合治疗早期口腔鳞状细胞癌

背景:早期口腔癌患者在节点复发后初次手术时应用选择性颈清扫术还是治疗性颈清扫术进行治疗的问题是一直存在争论的。      方法:在这项前瞻性、随机对照试验中,研究人员评估了单侧阶段T1或T2口腔鳞状细胞癌患者使用选择性淋巴结清扫术(在初次手术时同侧颈淋巴清扫术)和治疗淋巴结清扫术(观察等待之后进行淋巴结复发的颈淋巴结清扫术)对生存的影响。主要和次要终点分别是